In an attempt to ease norms for testing and introduction of new medicines in the country, the government has taken steps to fast-track approvals for clinical trials as well as launch of drugs already approved in other countries. Pharmaceutical companies planning to launch new drugs already approved outside India after conducting pre-clinical or toxicological studies on animals will not be required to repeat such studies in India for importing or manufacturing them here unless some specific concerns are raised, the Drugs Controller General of India, under the health ministry, said in a latest circular issued this week.
Subscribe Blogs & Newsletter
Recent Posts
- Clinical Trials and Human Subject Protection as per US FDA
- Understanding Clinical Data Management Services in Clinical Trials: A Breakdown
- Understanding Biostatistical Services in Clinical Trials: A Comprehensive Breakdown
- Telemedicine: How Remote Monitoring is Changing Clinical Research
- Putting Patients First: The Shift Towards Patient-Centric Clinical Trials
Archives
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- March 2022
- February 2022
- December 2021
- November 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- September 2020
- July 2020
- June 2020
- February 2020
- May 2019
- December 2018
- May 2018
- February 2018
- November 2017
- October 2017
- September 2017
- August 2017
Categories
- Biosimilar Clinical Trials
- CDSCO Regulations
- Clinical Data Management
- Clinical Research Industry
- Clinical Trial News
- COVID 19
- Decentralized Clinical Trials
- eCOA in Clinical Trials
- EMA Regulations
- Endocrinology or Diabetology Clinical Trials
- Herbal and Nutraceuticals
- ICH-GCP Guidelines
- Medical Device Clinical Trials
- Oncology Clinical Trials
- Ophthalmology Clinical Trials
- Pharmacovigilance Industry
- ProRelix Research News
- Rare Disease or Orphan Disease
- Real-World Evidence
- TGA Regulations
- Uncategorized
- US FDA Regulations